Clinical trials: Biliary Tract Cancer, open to volunteers
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Biliary Stricture, Bile Duct Cancer
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
Biliary stricture is mainly malignant in the adults and caused by several types of fatal malignancies such as pancreatic cancer, cholangiocarcinoma, and metastatic tumor, which have poor prognosis that the overall survival of…
- Conditions
- Biliary Stricture, Bile Duct Cancer, Pancreas Cancer
- Trial name
- ECCBILE (NCT06277531)
- Where
- 2 sites in China
- Volunteers
- 99 people
- Sponsor
- Peking University Third Hospital
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
- Trial name
- NCT06901622
- Testing
- Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Urothelial Carcinoma, Biliary Tract Cancer
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
his single-center phase II clinical study enrolls patients with unresectable locally advanced or metastatic HER2-overexpressing biliary tract cancer or urothelial carcinoma who have failed standard treatment.
- Conditions
- Urothelial Carcinoma, Biliary Tract Cancer, HER2
- Trial name
- SHIELD (NCT07506057)
- Testing
- Trastuzumab+Serplulimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiujuan Qu
Biliary Tract Cancer, DNA Damage Repair Deficiency
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
First-line gemcitabine plus cisplatin chemotherapy is the standard first-line treatment for unresectable or metastatic advanced biliary tract cancer and the optimal duration of the treatment is not mentioned in current clinical…
- Trial name
- OPTIMUM (NCT05222971)
- Testing
- Durvalumab, Olaparib
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Asan Medical Center
Biliary Tract Cancer
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea.
- Trial name
- NCT07151118
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Gallbladder Cancer, Initially Unresectable
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Study design: Prospective, single-arm, single-center phase II clinical study; Primary endpoint: Objective response rate via investigator, Safety; Secondary endpoints: disease control rate, disease-free survival, overall survival…
- Conditions
- Gallbladder Cancer, Initially Unresectable, the First Line Treatment
- Trial name
- NCT05757336
- Testing
- Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Lu Wang, MD, PhD
Incidence of Cholangiocarcinoma on Choledochal Cysts, Postoperative Complications in Choledochal Cysts
Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center
Choledochal cysts are congenital cystic dilatations of the intra and/or extrahepatic bile duct. They have been considered a rare entity of the child population.
- Conditions
- Incidence of Cholangiocarcinoma on Choledochal Cysts, Postoperative Complications in Choledochal Cysts, Choledochal Cyst Monitoring
- Trial name
- QuiCo (NCT05404503)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- María Teresa Moreno Asencio
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
- Trial name
- NCT06434597
- Testing
- SPH5030
- Where
- 30 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Biliary Tract Cancers
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment…
- Trial name
- NCT06564623
- Testing
- mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Biliary Cancer, Bile Duct Cancer
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Background: Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with advanced BTC have few treatment options, and their survival rates are very low.
- Conditions
- Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
- Trial name
- NCT05849480
- Testing
- oxaliplatin, capecitabine, Keytruda
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Biliary Tract Cancer
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
This prospective real-world study aims to evaluate the effectiveness and safety of an alternating treatment regimen combining hepatic arterial infusion chemotherapy (HAIC) with systemic chemotherapy, with or without adebrelimab…
- Trial name
- NCT07569679
- Testing
- HAIC, Gemcitabine plus Cisplatin, Adebrelimab
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Air Force Military Medical University, China
Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers
Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
This is a multicenter Phase 1b/2 clinical trial investigating the efficacy and safety of a combination regimen of Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab in treatment-naïve patients with unresectable, locally…
- Trial name
- GENTIS (NCT06893380)
- Testing
- Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- CHA University
Liver Cirrhosis, Hepatocellular Carcinoma (HCC)
A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions
Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis.
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Cholangitis, Sclerosing
- Trial name
- VOCAL2 (NCT06864195)
- Where
- United Kingdom
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Biliary Tract Cancer, Cholangiocarcinoma
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC).
- Trial name
- NCT06648057
- Testing
- lenvatinib plus pembrolizumab
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Biliary Tract Cancer
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.
- Trial name
- NCT06620848
- Testing
- HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Zhongshan Hospital
Choledochal Cyst
Timing of Operation in Children With a Prenatal Diagnosis of Choledochal Cyst
In this prospective study, we tried to select the operation time according to the cyst size and evaluate the treatment effect.
- Trial name
- CDCPS (NCT05620485)
- Testing
- laparoscopic-assisted CDC excision and hepaticojejunostomy
- Volunteers
- 30 people
- Sponsor
- Guangzhou Women and Children's Medical Center